Dr Jane Wolstenholme
BA(Hons) (London), MSc (York), PhD (Nottingham)
Senior Health Economist, HERC
Jane Wolstenholme has 20 years of experience of conducting economic evaluations for health policy makers and exploring methodological issues relating to the design and analysis of economic evaluations. She has been a health economist at HERC since 1998.
Her main interests include designing and conducting economic evaluations alongside trials and cost-effectiveness models. She is principal investigator and co-applicant on a wide variety of funded research projects, across a number of disease areas and health-care technologies, including cancer, chronic kidney disease, obesity, mental health, point of care diagnostics. She is a health economics advisor for the RDS South Central and for the NIHR Diagnostics Evidence Co-Operative, Oxford. She supervises MSc and DPhil students. Jane has published widely and is co-author of a major OUP text book ‘Applied Methods of Cost-effectiveness Analysis in Health Care’.
Preference-based measures to obtain health state utility values for use in economic evaluations with child-based populations: a review and UK-based focus group assessment of patient and parent choices.
Wolstenholme JL. et al, (2018), Qual Life Res, 27, 1769 - 1780
Early use of Antibiotics for at Risk CHildren with InfluEnza (ARCHIE): protocol for a double-blind, randomised, placebo-controlled trial.
Wang K. et al, (2018), BMJ open, 8, e021144 - e021144
Measuring quality of life of people with predementia and dementia and their caregivers: a systematic review protocol.
Landeiro F. et al, (2018), BMJ Open, 8
Recruitment to the "Breast-Activity and Healthy Eating After Diagnosis" (B-AHEAD) Randomized Controlled Trial.
Pegington M. et al, (2018), Integr Cancer Ther, 17, 131 - 137
Estimating the sensitivity of a prostate cancer screening programme for different PSA cut-off levels: A UK case study.
Leal J. et al, (2018), Cancer Epidemiol, 52, 99 - 105